{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:00:38Z","timestamp":1789203638795,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.leukres.2013.09.021","type":"journal-article","created":{"date-parts":[[2013,9,29]],"date-time":"2013-09-29T05:35:37Z","timestamp":1380432937000},"page":"1711-1718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Flavia Cunha","family":"Vasconcelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Nestal de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Moellmann-Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.09.021_bib0005","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0010","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2013.09.021_bib0015","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.021_bib0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2009.08066.x","article-title":"BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL\/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukemia","volume":"149","author":"Lucas","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.09.021_bib0025","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.leukres.2011.01.012","article-title":"Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of BCR-ABL phosphorylation","volume":"35","author":"Shibata","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.09.021_bib0030","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2013.09.021_bib0035","first-page":"671702","article-title":"The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk Res Treatment"},{"key":"10.1016\/j.leukres.2013.09.021_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-1-4615-4811-9_52","volume":"457","author":"Turkina","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.leukres.2013.09.021_bib0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.leukres.2004.06.004","article-title":"BCRP mRNA expression v. clinical outcome in 40 adult AML patients","volume":"29","author":"Uggla","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.09.021_bib0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.leukres.2013.09.021_bib0055","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.021_bib0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.021_bib0065","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.leu.2402541","article-title":"BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia","volume":"16","author":"Steinbach","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.09.021_bib0070","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.09.021_bib0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.leukres.2003.09.002","article-title":"Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients","volume":"28","author":"Galimberti","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.09.021_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","article-title":"Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"An Acad Bras Cienc"},{"issue":"7","key":"10.1016\/j.leukres.2013.09.021_bib0085","doi-asserted-by":"crossref","first-page":"e22429","DOI":"10.1371\/journal.pone.0022429","article-title":"Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters","volume":"6","author":"Lebedeva","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.021_bib0090","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res"},{"issue":"March","key":"10.1016\/j.leukres.2013.09.021_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-5956-10-23","article-title":"A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line","volume":"10","author":"Corr\u00eaa","year":"2012","journal-title":"Proteome Sci"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0100","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Maia","year":"2011","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.021_bib0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0928-0987(00)00097-X","article-title":"Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines","volume":"11","author":"Van Der Sandt","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.leukres.2003.10.015","article-title":"Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines","volume":"28","author":"Dogan","year":"2004","journal-title":"Leuk Res"},{"issue":"18","key":"10.1016\/j.leukres.2013.09.021_bib0115","first-page":"6635","article-title":"Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP-overexpressing cells","volume":"61","author":"Honjo","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2013.09.021_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4614-6176-0_8","article-title":"Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms","volume":"779","author":"Bisen","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0125","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.021_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hon.714","article-title":"ABCG2 (BCRP) expression in normal and malignant hematopoietic cells","volume":"21","author":"Abbott","year":"2003","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.021_bib0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00280-004-0866-2","article-title":"Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP\/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors","volume":"55","author":"Garimella","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.leukres.2013.09.021_bib0140","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-10-0510","article-title":"c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells","volume":"9","author":"Porro","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.leukres.2013.09.021_bib0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.021_bib0150","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2013.09.021_bib0155","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0160","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3324\/haematol.2012.070268","article-title":"Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells","volume":"98","author":"Hiwase","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2013.09.021_bib0165","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2013.09.021_bib0170","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.021_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2013.09.021_bib0180","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"issue":"1\u20133","key":"10.1016\/j.leukres.2013.09.021_bib0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.febslet.2004.03.064","article-title":"Human limbal epithelium contains side population cells expressing the ATP-binding cassette transporter ABCG2","volume":"565","author":"Watanabe","year":"2004","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.leukres.2013.09.021_bib0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neures.2005.01.013","article-title":"Functional expression of ABCG2 transporter in human neural stem\/progenitor cells","volume":"52","author":"Islam","year":"2005","journal-title":"Neurosci Res"},{"issue":"10","key":"10.1016\/j.leukres.2013.09.021_bib0195","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","article-title":"Cancer stem cells in solid tumours: accumulating evidence and unresolved questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2013.09.021_bib0200","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0145-2126(00)00156-9","article-title":"Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukemia","volume":"25","author":"Ferrao","year":"2001","journal-title":"Leuk Res"},{"issue":"June (6)","key":"10.1016\/j.leukres.2013.09.021_bib0205","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00432-012-1170-x","article-title":"ABCB1 genetic variation and P-glycoprotein expression\/activity in a cohort of Brazilian acute myeloid leukemia patients","volume":"138","author":"Scheiner","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"October (4)","key":"10.1016\/j.leukres.2013.09.021_bib0210","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.leukres.2013.09.021_bib0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.leukres.2013.09.021_bib0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Hirayama","year":"2008","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.leukres.2013.09.021_bib0225","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s11095-007-9278-4","article-title":"Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar","volume":"24","author":"Bihorel","year":"2007","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.leukres.2013.09.021_bib0230","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/10428194.2012.715345","article-title":"Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2","volume":"54","author":"Eadie","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300338X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300338X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T21:19:06Z","timestamp":1596575946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261300338X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S014521261300338X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}